August 2017

New Indications

Atozet (ezetimibe/atorvastatin (as calcium trihydrate)) is now also indicated in patients with coronary heart disease and a history of acute coronary syndrome taking their maximum tolerated dose of atorvastatin and in need of additional lowering of low density lipoprotein cholesterol in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy.

Opdivo (nivolumab (rch)) as monotherapy is now also indicated for the treatment of adults with relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin. The approval of this indication is based on objective response rate.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au